Phil Inc. Partners with RedHill Biopharma to Increase Access to Talicia®

Celldex Therapeutics, Inc. has initiated their Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE) with the dosing of the first patient. EoE is a chronic inflammatory disease that affects the esophagus and is the most common form of eosinophilic gastrointestinal disease. The objective of this study is to assess the effectiveness and safety of subcutaneous barzolvolimab in patients w..